Thyroid hormones and the cardiovascular system: Pathophysiology and interventions

Biomedicine and Pharmacotherapy

Volumn 63, Issue 10, 2009, Pages 742-753

  Cini, G ^a   Carpi, A ^a   Mechanick, J ^b   Cini, L ^a   Camici, M ^a   Galetta, F ^a   Giardino, R ^c   Russo, M A ^d,f   Iervasi, G ^e  

^a UNIVERSITY OF PISA   (Italy)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^f IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIIODOTHYROPROPIONIC ACID; LIOTHYRONINE; PLACEBO; STRUCTURAL PROTEIN; THYROID HORMONE; THYROID HORMONE DERIVATIVE; THYROXINE; THYROXINE DERIVATIVE; UNCLASSIFIED DRUG;

CARDIOVASCULAR SYSTEM; CHRONOTROPISM; CLINICAL TRIAL; DISEASE SEVERITY; GENOMICS; HEART FAILURE; HUMAN; INOTROPISM; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYMPTOMATOLOGY; THYROID DISEASE; THYROID FUNCTION; UNSPECIFIED SIDE EFFECT;

ANIMALS; CARDIOVASCULAR DISEASES; GENOMICS; HEART FAILURE; HUMANS; SYSTEMS BIOLOGY; THYROID DISEASES; THYROID FUNCTION TESTS; THYROID HORMONES;

EID: 71749085029     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2009.08.003     Document Type: Review

References (151)

1. Francois M., and Delemer B. What's new in the couple thyroid and heart in 2008?. Ann. Endocrinol 69 Suppl. 1 (2008) 37-43
2. De Groot L.J. Non-thyroidal illness syndrome is a manifestation of hypothalamic-pituitary dysfunction, and in view of current evidence, should be treated with appropriate replacement therapies. Critical Care Clinics 22 1 (2006) 57-86
3. Yen P.M. Physiological and molecular basis of thyroid hormone action. Physiol Rev 81 (2001) 1097-1142
4. Brent G.A. The molecular basis of thyroid hormone action. N Engl J Med 31 (1994) 847-853
5. Bianco A.C., Salvatore D., Gereben B., et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 23 (2002) 38-89
6. Maia A.L., Kim B.W., Huang S.A., Harney J.W., and Larsen P.R. Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J Clin Invest 115 (2005) 2524-2533
7. Everts M.E., Verhoeven F.A., Bezstarosti K., et al. Uptake of thyroid hormones in neonatal rat cardiac myocytes. Endocrinology 137 (1996) 4235-4242
8. Sabatino L., Iervasi G., Ferrazzi P., et al. A study of iodothyronine 5′-monodeiodinase activities in normal and pathological tissues in man and their comparison with activities in rat tissues. Life Sci 68 (2000) 191-202
9. Wassen F.W., Schiel A.E., Kuiper G.G., et al. Induction of thyroid hormone degrading deiodinase in cardiac hypertrophy and failure. Endocrinology 143 (2002) 2812-2815
10. Pilo A., Iervasi G., Vitek F., et al. Thyroidal and peripheral production of 3,5,3′-triiodothyronine in humans by mental analysis. Am J Physiol 258 (1990) E715-E726
11. Klein I., and Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 244 (2004) 501-507
12. Kahaly G.J., and Dillmann W.H. Thyroid hormone action in the heart. Endocr Rev 26 (2005) 704-728
13. Basset J.H., Harvey C.B., and Williams G.R. Mechanisms of thyroid hormone receptor-specific nuclear and extra nuclear actions. Mol Cell Endocrinol 213 (2003) 1-11
14. Lazar M.A., and Chin W.W. Nuclear thyroid hormone receptors. J Clin Invest 86 (1990) 1777-1782
15. Lazar M.A. Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr Rev 14 (1993) 184-193
16. Wu Y., and Koenig R.J. Gene regulation by thyroid hormone. Trends Endocrinol Metab 11 (2000) 207-211
17. Shibusawa N., Hollenberg A.N., and Wondisford F.E. Thyroid hormone receptor DNA binding is required for both positive and negative gene regulation. J Biol Chem 278 (2003) 732-738
18. Davis P.J., Shih A., Lin H.Y., et al. Thyroxine promotes association of mitogen activated protein kinase and nuclear thyroid hormone receptor (TR) and causes serine phosphorylation of TR. J Biol Chem 275 (2000) 38032-38039
19. Lazar M.A. Thyroid hormone action: a binding contract. J Clin Invest 112 (2003) 497-499
20. Ojamaa K., Petrie J.F., and Balkman C. Posttranscriptional modification of myosin heavy-chain gene expression in the hypertrophied rat myocardium. Proc Natl Acad Sci USA 91 (1994) 3468-3472
21. Frank K.F., Bölck B., Erdmann E., et al. Sarcoplasmic reticulum Ca2+-ATPase modulates cardiac contraction and relaxation. Cardiovasc Res 57 (2003) 20-27
22. Koss K.L., and Kranias E.G. Phospholamban: a prominent regulator of myocardial contractility. Circ Res 79 (1996) 1059-1063
23. Kiss E., Jakab G., Kranias E.G., and Edes I. Thyroid hormone-induced alterations in phospholamban protein expression: regulatory effects on sarcoplasmic reticulum Ca2+ transport and myocardial relaxation. Circ Res 75 (1994) 245-251
24. Hiroi Y., Kim H.-H., Ying H., et al. Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci USA 103 (2006) 14104-14109
25. Wrutniak-Cabello C., Casas F., and Cabello G. Thyroid hormone action in mitochondria. J Mol Endocrinol 26 (2001) 67-77
26. Sun Z., Ojamaa K., Coetzee W.A., Artman M., and Klein I. Effects of thyroid hormone on action potential and repolarization currents in rat ventricular myocytes. Am J Physiol Endocrinol Metab 278 (2000) E302-E307
27. Shi W., Wymore R., Yu H., et al. Distribution and prevalence of hyperpolarization-activated cation channel (HCN) mRNA expression in cardiac tissues. Circ Res 85 (1999) e1-e6
28. Pachucki J., Burmeister L.A., and Larsen P.R. Thyroid hormone regulates hyperpolarization-activated cyclic nucleotide-gated channel (HCN2) mRNA in the rat heart. Circ Res 85 (1999) 498-503
29. Klein I., and Ojamaa K. Thyroid hormone targeting the vascular smooth muscle cell. Circ Res 88 (2001) 260-261
30. Ojamaa K., Klemperer J.D., and Klein I. Acute effects of thyroid hormone on vascular smooth muscle. Thyroid 6 (1996) 505-512
31. Colantuoni A., Marchiafava P.L., Lapi D., et al. Effects of tetraiodothyronine and triiodothyronine on hamster cheek pouch microcirculation. Am J Physiol Heart Circ Physiol 288 (2005) H1931-H1936
32. Mizuma H., Murakami M., and Mori M. Thyroid hormone activation in human vascular smooth muscle cells: expression of type II iodothyronine deiodinase. Circ Res 88 (2001) 313-318
33. Park K., Dai H., Ojamaa K., Lowenstein E., Klein I., and Sellke F. Direct vasomotor effect of thyroid hormones on rat skeletal muscle resistance arteries. Anesth Analg 85 (1997) 734-738
34. Vargas F., Moreno J.M., Rodriguez-Gomez I., et al. Vascular and renal function in experimental thyroid disorders. Eur J Endocrinol 154 (2006) 197-212
35. Fukuyama K., Ichiki T., Takeda K., et al. Downregulation of vascular angiotensin II type 1 receptor by thyroid hormone. Hypertension 41 (2003) 598-603
36. Fommei E., and Iervasi G. The role of thyroid hormone in blood pressure homeostasis: evidence from short-term hypothyroidism in humans. J Clin Endocrinol Metab 87 (2002) 1996-2000
37. Dernellis J., and Panaretou M. Effects on thyroid replacement therapy on arterial blood pressure in patients with hypertension and hypothyroidism. Am Heart J 143 (2002) 718-724
38. Fish S.A., and Mandel S.J. The blood in thyrotoxicosis. In: Braverman L., and Utiger R. (Eds). Werner and Ingbar's the thyroid. 9th ed (2005), Lippincott-Raven Publishers, Philadelphia, PA 595-598
39. Biondi B., and Cooper D. The clinical significance of subclinical thyroid disfunction. Endocr Rev 29 1 (2008 Feb) 76-131
40. Iervasi G., Molinaro S., Landi P., et al. Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med 167 (2007) 1526-1532
41. Biondi B., Palmieri E.A., Lombardi G., et al. Subclinical hypothyroidism and cardiac function. Thyroid 12 (2002) 505-510
42. Di Bello V., Monzani F., Giorgi D., et al. Ultrasonic myocardial textural analysis in subclinical hypothyroidism. J Am Soc Echocardiogr 13 (2000) 832-840
43. Ripoli A., Pingitore A., Favilli B., et al. Does subclinical hypothyroidism affect cardiac pump performance? Evidence from a magnetic resonance imaging study. J Am Coll Cardiol 45 (2005) 439-445
44. Galetta F., Franzoni F., Fallahi P., et al. Heart rate variability and Q T dispersion in patients with subclinical hypothyroidism. Biomed Pharmacother 60 (2006) 425-430
45. Vitale G., Galderisi M., Lupoli G.A., et al. Left ventricular myocardial impairment in subclinical hypothyroidism assessed by a new ultrasound tool: pulsed tissue Doppler. J Clin Endocrinol Metab 87 (2002) 4350-4355
46. Aghini-Lombardi F., Di Bello V., Talini E., et al. Early textural and functional alterations of left ventricular myocardium in mild hypothyroidism. Eur J Endocrinol 155 (2006) 3-9
47. Franzoni F., Galetta F., Fallahi P., et al. Effect of l-thyroxine treatment on left ventriculare function in subclinical hypothyroidism. Biomed Pharmacother 60 (2006) 431-436
48. Monzani F., Di Bello V., Caraccio N., et al. Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study. J Clin Endocrinol Metab 86 (2001) 1110-1115
49. Crowley Jr. W.F., Ridgway E.C., Bough E.W., et al. Non-invasive evaluation of cardiac function in hypothyroidism: response to gradual thyroxine replacement. N Engl J Med 296 (1977) 1-6
50. Yazici M., Gorgulu S., Sertbas Y., et al. Effects of thyroxin therapy on cardiac function in patients with subclinical hypothyroidism: index of myocardial performance in the evaluation of left ventricular function. Int J Cardiol 95 (2004) 135-143
51. Kahaly G.J. Cardiovascular and atherogenic aspects of subclinical hypothyroidism. Thyroid 10 (2000) 665-679
52. Peleg R.K., Efrati S., Benbassat C., Fygenzo M., and Golik A. The effect of levothyroxine on arterial stiffness and lipid profile in patients with subclinical hypothyroidism. Thyroid 18 8 (2008 Aug) 825-830
53. Duman D., Demirtunc R., Sahin S., and Esertas K. The effects of simvastatin and levothyroxine on intima-media thickness of the carotid artery in female normolipemic patients with subclinical hypothyroidism: a prospective, randomized-controlled study. J Cardiovasc Med 8 12 (2007 Dec) 1007-1011
54. Mattace-Raso F.U., Van der Cammen T.J., Hofman A., et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 113 (2006) 657-663
55. Laurent S., Boutouyrie P., Asmar R., et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37 (2001) 1236-1241
56. Monzani F., Caraccio N., Kozakowa M., et al. Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 89 (2004) 2099-2106
57. Nagasaki T., Inaba M., Henmi Y., et al. Decrease in carotid intima-media thickness in hypothyroid patients after normalization of thyroid function. Clin Endocrinol (Oxf) 59 (2003) 607-612
58. Taddei S., Caraccio N., Virdis A., et al. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab 88 (2003) 3731-3737
59. Bauer D.C., Ettinger B., and Browner W.S. Thyroid function and serum lipids in older women: a population-based study. Am J Med 104 (1998) 546-551
60. Pirich C., Mullner M., and Sinzinger H. Prevalence and relevance of thyroid dysfunction in 1922 cholesterol screening participants. J Clin Epidemiol 53 (2000) 623-629
61. Valdemarsson S., Hansson P., Hedner P., and Nilsson-Ehle P. Relations between thyroid function, hepatic and lipoprotein lipase activities, and plasma lipoprotein concentrations. Acta Endocrinol 104 (1983) 50-56
62. Chen H.S., Wu T.E., Jap T.S., et al. Subclinical hypothyroidism is a risk factor for nephropathy and cardiovascular diseases in Type 2 diabetic patients. Diabet Med 24 (2007) 1336-1344
63. Chonchol M., Lippi G., Salvagno G., et al. Prevalence of subclinical hypothyroidism in patients with chronic kidney disease. Clin J Am Soc Nephrol 3 (2008) 1296-1300
64. Chadarevian R., Bruckert E., Leenhardt L., Giral P., Ankri A., and Turpin G. Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism. J Clin Endocrinol Metab 86 (2001) 732-737
65. Muller B., Tsakiris D.A., Roth C.B., Guglielmetti M., Staub J.J., and Marbet G.A. Haemostatic profile in hypothyroidism as potential risk factor for vascular or thrombotic disease. Eur J Clin Invest 31 (2001) 131-137
66. Jorde R., Fighenschau Y., and Hansen J.B. Hemostatic function in subjects with mild subclinical hypothyroidism. The Tromso study. Thromb Haemost 95 (2006) 750-751
67. Canturk Z., Cetinarslan B., Tarkun I., Canturk N.Z., Ozden M., and Duman C. Hemostatic system as a risk factor for cardiovascular disease in women with subclinical hypothyroidism. Thyroid 13 (2003) 971-977
68. Sawin C.T., Geller A., Wolf P.A., et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older patients. N Engl J Med 331 (1994) 1249-1252
69. Osman F., Gammage M.D., Sheppard M.C., et al. Clinical review 142: cardiac dysrhythmias and thyroid dysfunction: the hidden menace?. J Clin Endocrinol Metab 87 (2002) 963-967
70. Petretta M., Bonaduce D., Spinelli L., et al. Cardiovascular haemodynamics and cardiac autonomic control in patients with subclinical and overt hyperthyroidism. Eur J Endocrinol 145 (2001) 691-696
71. Biondi B., Fazio S., Coltorti F., et al. Clinical case seminar: reentrant atrioventricular nodal tachycardia induced by levothyroxine. J Clin Endocrinol Metab 83 (1998) 2643-2645
72. Aras D., Maden O., Ozdemir O., et al. Simple electrocardiographic markers for the prediction of paroxysmal atrial fibrillation in hyperthyroidism. Int J Cardiol 99 (2005) 59-64
73. Klein I., and Hong C. Effects of thyroid hormone on cardiac size and myosin content of the heterotopically transplanted rat heart. J Clin Invest 77 (1986) 1694-1698
74. Kobori H., Ichihara A., Miyashita Y., Hayashi M., and Saruta T. Local renin-angiotensin system contributes to hyperthyroidism-induced cardiac hypertrophy. J Endocrinol 160 (1999) 43-47
75. Haider A.W., Larson M.G., Benjamin E.J., and Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 32 (1998) 1454-1459
76. Mercuro G., Panzuto M.G., Bina A., et al. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. J Clin Endocrinol Metab 85 (2000) 159-164
77. Volzke H., Robinson D.M., Schminke U., et al. Thyroid function and carotid wall thickness. J Clin Endocrinol Metab 89 (2004) 2145-2149
78. Dorr M., Robinson D.M., Wallaschofski H., et al. Low serum thyrotropin is associated with high plasma fibrinogen. J Clin Endocrinol Metab 91 (2006) 530-534
79. Erem C. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity. Clin Endocrinol (Oxf) 64 (2006) 323-329
80. Volzke H., Schwahn C., Wallaschofski H., and Dorr M. Review: the association of thyroid dysfunction with all cause and circulatory mortality: is there a causal relationship?. J Clin Endocrinol Metab 92 (2007) 2421-2429
81. Cappola A.R., Fried L.P., Arnold A.M., et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 295 (2006) 1033-1041
82. Fazio S., Palmieri E.A., Lombardi G., and Biondi B. Effects of thyroid hormone on the cardiovascular system. Recent Progr Horm Res 59 (2004) 31-50
83. Olshausen K., Bisehofr S., Kahaly G.J., et al. Cardiac arryhthmias and heart rate in hyperthyroidism. Am J Cardiol 63 (1989) 930-933
84. Wustmann K., Kueera I.P., Zanehi A., et al. Activation of electrical triggers of atrial fibrillation in hyperthyroidism. J Clin Endocrinol Metab 93 (2008) 2104-2108
85. Freedberg A.S., Papp J.G., and Vaugham Williams E.M. The effect of altered thyroid state on atrial intracellular potentials. J Physiol 207 (1970) 357-369
86. Arnsdorf M.F., and Childers R.W. Atrial electrophysiology in experimental hyperthyroidism in rabbits. Circ Res 26 (1970) 575-581
87. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 415 (2002) 219-226
88. Li D., Zhang L., Kneller I., and Nattel S. Potential ionic mechanism for repolarization differences between canine right and left atrium. Circ Res 88 (2001) 1168-1175
89. Ma M.I., Watanabe K., Watanabe H., et al. Different gene expression of potassium channels by thyroid hormone and an antithyroid drug between the atrium and ventricle of rats. Jpn Heart J 44 (2003) 101-110
90. Nishiyama A., Kambe F., Kamiya K., Seo H., and Toyama J. Effects of thyroid status on expression of voltage-gated potassium channels in rat left ventricle. Cardiovasc Res 40 (1998) 343-351
91. Abe A., Yamamoto T., Isome M., et al. Thyroid hormone regulates expression of shaker-related potassium channel mRNA in rat heart. Biochem Biophys Res Commun 245 (1998) 226-230
92. Watanabe H., Ma M., Washizuka T., et al. Thyroid hormone regulates mRNA expression and currents of ion channels in rat atrium. Biochem Biophys Res Commun 308 (2003) 439-444
93. Hu Y., Jones S.V., and Dillmann W.H. Effects of hyperthyroidism on delayed rectifier potassium currents in left and right murine atrium. Am J Physiol Heart Circ Physiol 289 (2005) H1448-H1455
94. Chen Y.C., Chen S.A., Chen Y., Chang M.S., Chan P., and Lin C.I. Effects of thyroid hormone on the arrhythmogenic activity of pulmonary vein cardiomyocytes. J Am Coll Cardiol 39 (2002) 366-372
95. Chen S.A., Hsieh M.H., Tai C.T., et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation 100 (1999) 1879-1886
96. Chen Y.I., Chen S.A., Chang M.S., and Lin C.I. Arrhythmogenic activity of cardiac muscle in pulmonary veins of the dog: implication for the genesis of atrial fibrillation. Cardiovasc Res 48 (2000) 265-273
97. Klein I., and Danzi S. Thyroid disease and the heart. Circulation 116 (2007) 1725-1735
98. Jessup M., and Brozena S. Heart failure. N Engl J Med 348 (2003) 2007-2018
99. Francis G.S. Pathophysiology of chronic heart failure. Am J Med 110 Suppl. 7A (2001) 37S-46S
100. Mann D.L. Mechanisms and models in heart failure - a combinatorial approach. Circulation 100 (1999) 999-1008
101. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. Am J Cardiol 20 (1992) 248-254
102. Klein I. Endocrine disorders and cardiovascular disease in Braunwald's: heart disease. A textbook of cardiovascular medicine. 8th ed. (2008), Saunders, Philadelphia p. 2033-2047
103. Ascheim D.D., and Hryniewicz K. Thyroid hormone metabolism in patients with congestive heart failure: the low triiodothyronine state. Thyroid 12 (2002) 511-515
104. Selvaraj N., Bobby Z., and Sridhar M.G. Is euthyroid sick syndrome a defensive mechanism against oxidative stress?. Med Hypotheses 71 (2008) 404-405
105. Hollander J.M., and Mechanick J.I. Nutrition support and the chronic critical illness syndrome. Nutr Clin Pract 21 6 (2006 Dec) 587-604
106. McIver B., and Gorman C.A. Euthyroid sick syndrome: an overview. Thyroid 7 (1997) 125-132
107. Katzeff H.L., Powell S.R., and Ojamaa K. Alterations in cardiac contractility and gene expression during low-T3 syndrome: prevention with T3. Am J Physiol 273 (1997) E951-E956
108. Kimura T., Kanda T., Kuwabara A., Shinohara H., and Kobayashi I. Participation of the pituitary-thyroid axis in the cardiovascular system in elderly patients with congestive heart failure. J Med 28 (1997) 75-80
109. Sylvén C., Jansson E., Sotonyi P., et al. Cardiac nuclear hormone receptor mRNA in heart failure in man. Life Sci 59 (1996) 1917-1922
110. Kinugawa K., Yonekura K., Ribeiro R.C., et al. Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy. Circ Res 89 (2001) 591-598
111. Mai W., Janier M.F., Allioli N., et al. Thyroid hormone receptor alpha is a molecular switch of cardiac function between fetal and postnatal life. Proc Natl Acad Sci USA 101 (2004) 10332-10337
112. Kinugawa K., Minobe W.A., Wood W.M., et al. Signaling pathways responsible for fetal gene induction in the failing human heart: evidence for altered thyroid hormone receptor gene expression. Circulation 103 (2001) 1089-1094
113. Razeghi P., Young M.E., Alcorn J.L., et al. Metabolic gene expression in fetal and failing human heart. Circulation 104 (2001) 2923-2931
114. Izumo S., Lompré A.M., Matsuoka R., et al. Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. Interaction between hemodynamic and thyroid hormone-induced signals. J Clin Invest 79 (1987) 970-977
115. Haghighi K., Schmidt A.G., Hoit B.D., et al. Superinhibition of sarcoplasmic reticulum function by phospholamban induces cardiac contractile failure. J Biol Chem 276 (2001) 24145-24152
116. Hein S., Kostin S., Heling A., et al. The role of cytoskeleton in heart failure. Cardiovasc Res 45 (2000) 273-278
117. Lee H.W., Klein L.E., Raser J., et al. An activator protein-1 (AP-1) response element on pro alpha1(I) collagen gene is necessary for thyroid hormone-induced inhibition of promoter activity in cardiac fibroblasts. J Mol Cell Cardiol 30 (1998) 2495-2506
118. Yao J., and Eghbali M. Decreased collagen mRNA and regression of cardiac fibrosis in the ventricular myocardium of the tight skin mouse following thyroid hormone treatment. Cardiovasc Res 26 (1992) 603-607
119. Wong K., Boheler K.R., and Petrou M. Pharmacological modulation of pressure-overload cardiac hypertrophy: changes in ventricular function, extracellular matrix, and gene expression. Circulation 96 (1997) 2239-2246
120. Janicki J.S., Brower G.L., Gardner J.D., et al. The dynamic interaction between matrix metalloproteinase activity and adverse myocardial remodeling. Heart Fail Rev 9 (2004) 33-42
121. Emdin M., Passino C., Prontera C., et al. Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin Chem Lab Med 42 (2004) 627-636
122. Hamilton M.A., Stevenson L.W., Luu M., et al. Altered thyroid hormone metabolism in advanced heart failure. J Am Coll Cardiol 16 (1990) 9-15
123. Kozdag G., Ural D., Vural A., et al. Relation between free triiodothyronine/free thyroxine ratio, echocardiographic parameters and mortality in dilated cardiomyopathy. Eur J Heart Fail 7 (2005) 113-118
124. Pingitore A., and Iervasi G. Triiodothyronine (T3) effects on cardiovascular system in patients with heart failure. Recent Patents Cardiovasc Drug Discov 3 (2008) 19-27
125. Pingitore A., Lionetti V., and Forini F. Synthetic thyroid hormone and thyroid hormone analogues of heart failure. In: Iervasi G., and Pingitore A. (Eds). Thyroid and heart failure (2009), Springer-Verlag, Italia
126. Malik F.S., Mehra M.R., Uber P.A., et al. Intravenous thyroid hormone supplementation in heart failure with cardiogenic shock. J Card Fail 5 (1999) 31-37
127. Hamilton M.A., Stevenson L.W., Fonarow G.C., et al. Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. Am J Cardiol 81 (1998) 443-447
128. Pingitore A., Galli E., Barison A., et al. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low T3 syndrome: a randomized, placebo-controlled study. J Clin Endocrinol Metab 93 (2008) 1351-1358
129. Iervasi G., Emdin M., Colzani RMP, et al. Beneficial effects of long-term triiodothyronine (T3) infusion in patients with advanced heart failure and low T3 syndrome. In: Kimchi A, editor. Heart disease: new trends in research, diagnosis and treatment. Medimomd, Bologna, p. 549-553.
130. Moruzzi P., Doria E., Agostoni P.G., Capacchione V., and Sganzerla P. Usefulness of l-thyroxine to improve cardiac and exercise performance in idiopathic dilated cardiomyopathy. Am J Cardiol 73 (1994) 374-378
131. Moruzzi P., Doria E., and Agostoni P.G. Medium-term effectiveness of l-thyroxine treatment in idiopathic dilated cardiomyopathy. Am J Med 101 (1996) 461-467
132. Stathatos N., Levetan C., Burman K., and Wartofsky L. The controversy of the treatment of critically ill patients with thyroid hormone. Best Pract Res Clin Endocrinol Metab 15 (2001) 465-478
133. Farwell A.P. Thyroid hormone therapy is not indicated in the majority of patients with the sick euthyroid syndrome. Endocr Pract 14 (2008) 1180-1187
134. Pantos C., Mourouzis I., Xinaris C., and Cokkinos D. Thyroid hormone and myocardial ischaemia. J Steroid Biochem Mol Biol 109 (2008) 314-322
135. Pantos C., Mourouzis I., Xinaris C., Papadopoulou-Daifoti Z., and Cokkinos D. Thyroid hormone and "cardiac metamorphosis": potential therapeutic implications. Pharmacol Therap 118 (2008) 277-294
136. Pennock G.D., Raya T.E., Bah J.J., et al. Cardiac effects of 3,5-diiodothyropropionic acid, a thyroid hormone analog with inotropic selectivity. J Pharmacol Exp Ther 263 (1992) 163-169
137. Morkin E., Pennock G., Spooner P.H., et al. Pilot studies on the use of 3,5-diiodothyropropionic acid, a thyroid hormone analog, in the treatment of congestive heart failure. Cardiology 97 (2002) 218-225
138. Morkin E., Ladenson P., Goldman S., et al. Thyroid hormone analogs for treatment of hypercolesterolemia and heart failure: past, present and future prospects. J Mol Cell Cardiol 37 (2004) 1137-1146
139. Goldman S., McCarren M., Morkin E., et al. DITPA a thyroid hormone analog to treat heart failure: phase II Trial VA Cooperative Study. J Card Fail 14 (2008) 796
140. Brent G.A., and Hershman J.M. Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. J Clin Endocrinol Metab 63 (1986) 1-8
141. Novitzky D., K Cooper D., and Reichart B. Hemodynamic and metabolic responses to hormonal therapy in brain-dead potential organ donors. Transplantation 43 (1987) 852-854
142. Washida M., Okamoto R., and Manaka D. Beneficial effect of combined 3,5,3-triiodothyronine and vasopressin administration on hepatic energy status and systemic hemodynamics after brain death. Transplantation 54 (1992) 44-49
143. Mariot J., Jacob F., and Voltz C. Hormonal therapy in human brain-dead potential organ donors: comparative study. Anesthesiology 73 (1990) A246
144. Goarin J.P., Cohen S., and Riou B. The effects of triiodothyronine on hemodynamic status and cardiac function in potential organ donors. Anesth Analg 83 (1996) 41-47
145. Bennett-Guerrero E., Jimenez J.L., and White W.D. Cardiovascular effects of intravenous triiodothyronine in patients undergoing coronary artery bypass graft surgery. J Am Med Assoc 275 (1996) 687-692
146. Klemperer J.D., Klein I., and Gomez M. Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med 333 (1995) 1522-1527
147. Mullis-Jansson S., Argenziano M., and Corwin S. A randomized double-blinded study of the effect of triiodothyronine on the cardiac function and morbidity after coronary bypass surgery. J Thorac Cardiovasc Surg 117 (1999) 1128-1135
148. Novitzky D., Human P.A., and Cooper D.K.C. Effect of triiodothyronine (T3) on myocardial high-energy phosphates and lactate after ischemia and cardiopulmonary bypass. J Thorac Cardiovasc Surg 96 (1988) 600-607
149. Novitzky D., Cooper D.K.C., and Swanepoel A. Inotropic effect of triiodothyronine (T3) in low cardiac output following cardioplegic arrest and cardiopulmonary bypass: and initial experience in patients undergoing open heart surgery. Eur J Cardiothorac Surg 3 (1989) 140-145
150. Novitzky D., Human P.A., and Cooper D.K.C. Inotropic effect of triiodothyronine (T3) following myocardial ischemia and cardiopulmonary bypass. An experimental study in pigs. Ann Thorac Surg 45 (1988) 50-55
151. Yokoyama Y., Novitzky D., Deal M.T., and Snow T.R. Facilitated recovery of cardiac performance by triiodothyronine following a transient ischemic insult. Cardiology 81 (1992) 34-45